ArticlePloS one2022

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.

Saskia Maletzke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.